CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03561649
NCT03561649N/ACompleted

Prediction of Adalimumab Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive Spondyloarthritis: Pilot Study

University Hospital, Grenoble·interventional·Posted Jun 19, 2018·Updated May 27, 2026

In Brief

A clinical study evaluating Adalimumab for Spondylitis, Ankylosing. Completed, enrolled 50 participants across 5 sites.

Detailed Summary

The main objective of this trial is to search for biomarkers associated with the success of adalimumab treatment in order to generate an algorithm to predict the response to this treatment at 6 months in spondyloarthritis and to define its metrological properties on this cohort. The algorithm will allow to better target patients who will have an important benefit/risk ratio for adalimumab treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
CollaboratorsSINNOVIAL

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 19, 2018
Enrollment StartJun 14, 2018
Primary CompletionDec 14, 2019
Study CompletionMay 7, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.0 years ago

Interventions

Adalimumabdrug

This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.